Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Esperion (ESPR)
NASDAQ:ESPR
Esperion (ESPR) Stock Price & Analysis
1,320 Followers
ESPR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.70 - $3.40
Previous Close$2.36
Volume1.22M
Average Volume (3M)7.30M
Market Cap
$410.71M
Enterprise Value$586.11M
Total Cash (Recent Filing)$82.25M
Total Debt (Recent Filing)$266.17M
Price to Earnings (P/E)-2.3
Beta1.22
Next Earnings
Jul 30, 2024EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding189,460,293
10 Day Avg. Volume11,870,497
30 Day Avg. Volume7,303,757
Standard Deviation0.27
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-0.98
Price to Sales (P/S)3.84
Price to Cash Flow (P/CF)-3.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.04
Enterprise Value/Gross Profit5.04
Enterprise Value/Ebitda-3.94
Forecast
1Y Price Target
$7.41Price Target Upside207.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Esperion News
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe new FDA label expands the total addressable market from 10 million to 70 million, opening up a significant new patient population for bempedoic acid.
Regulatory ApprovalFDA's recent approval of the expanded label for bempedoic acid positions Nexlizet and Nexletol as 'next after statins', enhancing their commercial potential.
Sales GrowthRevenue continues to grow, with NEXLETOL/NEXLIZET U.S. product revenue of $24.8 million for the quarter, indicating a solid upward trajectory for the product.
Bears Say
Financial PerformanceEsperion announced financial results, posting EPS significantly lower than estimates and consensus.
Market CompetitionGrowing competitive pressures from other drugs in development could further impact bempedoic acid's market position.
Market PenetrationThe durability of the initial progress in bempedoic acid sales is questionable given the limited market penetration of generic statins and the challenge of reaching a broad range of prescribers.
---
Ownership Overview
7.93% Insiders
13.16% Mutual Funds
42.94% Other Institutional Investors
35.97% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ESPR FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest stock price was $0.70 and its highest was $3.40 in the past 12 months.
What is Esperion’s market cap?
Currently, no data Available
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Jul 30, 2024 which is in 71 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on May 07, 2024. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.049 by $0.291.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -$0.18.
How many shares outstanding does Esperion have?
Esperion has 170,417,790 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of $0.34 in its last earnings report, beating expectations of $0.049. Following the earnings report the stock price went up 11.792%.
Which hedge fund is a major shareholder of Esperion?
Among the largest hedge funds holding Esperion’s share is Woodline Partners LP. It holds Esperion’s shares valued at 21M.
---
Esperion Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.41 (207.47% Upside)
$7.41 (207.47% Upside)
Blogger Sentiment
Bullish
ESPR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 6.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.09%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
48.15%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
---
ESPR Company Deck
---
ESPR Earnings Call
Q1 2024
0:00 / 0:00
---
ESPR Stock 12 Month Forecast
Average Price Target
$7.41
▲(207.47% Upside)
Technical Analysis
Best Analysts Covering ESPR
1 Year
1 Year Success Rate
10/26 ratings generated profit
1 Year Average Return
+30.61%
reiterated a buy rating 2 months ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of +30.61% per trade.
---